Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study.
Saved in:
| Title: | Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study. |
|---|---|
| Authors: | Yamaguchi Y; Pfizer Inc, Collegeville, Pennsylvania., Peeva E; Pfizer Inc, Cambridge, Massachusetts., Adiri R; Pfizer Pharmaceutical Israel LTD, Herzliya Pituach, Israel., Ghosh P; Pfizer Inc, Cambridge, Massachusetts., Napatalung L; Pfizer Inc, New York, New York; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York., Hamzavi I; Department of Dermatology, Henry Ford Hospital, Detroit, Michigan., Pandya AG; Palo Alto Foundation Medical Group, Sunnyvale, California; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas., Shore RN; Ronald N. Shore Dermatology, Rockville, Maryland., Ezzedine K; Department of Dermatology, Hôpital Henri Mondor, Creteil, France., Guttman-Yassky E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: emma.guttman@mountsinai.org. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2025 Apr; Vol. 92 (4), pp. 781-789. Date of Electronic Publication: 2024 Dec 19. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
